Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist

التفاصيل البيبلوغرافية
العنوان: Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
المؤلفون: Cinzia Quattrocchi, Patrizia Ferraboschi, L. Bartorelli, Luigi Moro, Roberta Bozzella, Giuseppe Celasco, Ferdinande Nicoletti
المصدر: Scopus-Elsevier
بيانات النشر: Georg Thieme Verlag KG, 2011.
سنة النشر: 2011
مصطلحات موضوعية: Male, medicine.medical_specialty, medicine.drug_class, Administration, Topical, Cortodoxone, Antiandrogens, CAS 19608-29-8, CB-03-01, antiandrogenic activity, hamster, rat, Cortexolone 17α-propionate, Pharmacology, urologic and male genital diseases, Antiandrogen, Flutamide, chemistry.chemical_compound, Subcutaneous injection, Settore BIO/10 - Biochimica, Cricetinae, Internal medicine, Drug Discovery, medicine, Animals, Rats, Wistar, Glucocorticoids, Progesterone, Mesocricetus, Cyproterone acetate, Androgen Antagonists, Biological activity, Androgen, Rats, Testosterone Propionate, Androgen receptor, Endocrinology, chemistry, Injections, Intravenous, Finasteride, Female, Propionates, Corticosterone, Orchiectomy, Gonadotropins
الوصف: The aim of this study was to investigate the antiandrogenic activity of a new monoester of cortexolone, cortexolone 17alpha-propionate (CAS 19608-29-8, CB-03-01). Although the compound displayed a strong local antiandrogenic activity in hamster's flank organ test, it did not exhibit antiandrogenic activity in rats after subcutaneous injection, nor did it affect gonadotropins hypersecretion when injected to parabiotic rats. As topical antiandrogen, the steroid resulted about 4 times more active than progesterone (CAS 57-83-0) and, when compared to known antiandrogen standards, it was about 3 times more potent than flutamide (CAS 13311-84-7), about 2 times more effective than finasteride (CAS 98319-26-7) and approximately as active as cyproterone acetate (CAS 427-51-0). Its pharmacological activity seemed to be primarily related to its ability to antagonistically compete at androgen receptor level; nevertheless its primary pharmacological target needs to be further investigated. Its topical activity, along with the apparent absence of systemic effects, anticipates this compound to have the potential of representing a novel and safe therapeutic approach for androgen-dependent skin disorders.
تدمد: 1616-7066
0004-4172
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ecf327390734e30ea634891a093e486
https://doi.org/10.1055/s-0031-1297043
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....1ecf327390734e30ea634891a093e486
قاعدة البيانات: OpenAIRE